AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

In addition, AstraZeneca, Daiichi Sankyo, and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed a Letter of Intent under the Temporary Access Process (pTAP). Together with the TLR ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...